Graham Wetherill
Overview
Explore the profile of Graham Wetherill including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
89
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
McLaughlin V, Channick R, Kim N, Frantz R, McConnell J, Melendres-Groves L, et al.
Pulm Circ
. 2022 Nov;
12(4):e12150.
PMID: 36381290
Macitentan is an oral endothelin receptor antagonist for the management of pulmonary arterial hypertension (PAH). The OPsumit® USers Registry (OPUS) and the OPsumit® Historical USers cohort (OrPHeUS) medical chart review...
2.
Biedermann P, Ong R, Davydov A, Orlova A, Solovyev P, Sun H, et al.
BMC Med Res Methodol
. 2021 Nov;
21(1):238.
PMID: 34727871
Background: The Observational Medical Outcomes Partnership (OMOP) Common Data Model (CDM) can be used to transform observational health data to a common format. CDM transformation allows for analysis across disparate...
3.
Vehreschild M, Taori S, Goldenberg S, Thalhammer F, Bouza E, Oene J, et al.
Eur J Clin Microbiol Infect Dis
. 2018 Nov;
38(1):199.
PMID: 30406879
The article "Fidaxomicin for the treatment of Clostridium difficile infection (CDI) in at-risk patients with inflammatory bowel disease, fulminant CDI, renal impairment or hepatic impairment: a retrospective study of routine...
4.
Vehreschild M, Taori S, Goldenberg S, Thalhammer F, Bouza E, Oene J, et al.
Eur J Clin Microbiol Infect Dis
. 2018 Aug;
37(11):2097-2106.
PMID: 30099637
Information is limited or lacking on fidaxomicin treatment of Clostridium difficile infection (CDI) in patients with inflammatory bowel disease, fulminant or life-threatening CDI, severe renal impairment, moderate-to-severe hepatic impairment and...
5.
Labruyere J, Hartley C, Rogers K, Wetherill G, McConnell J, Dennis R
Vet Radiol Ultrasound
. 2008 Apr;
49(2):165-71.
PMID: 18418998
Vitreous degeneration is common in dogs and may be associated with cataract formation. Vitreous degeneration may be identified using B-mode ultrasonography and appears as multiple, small, motile, point-like echoes within...
6.
Menter A, Hamilton T, Toth D, Leung H, Wetherill G, Hennessey B, et al.
Int J Dermatol
. 2007 Jun;
46(6):637-48.
PMID: 17550570
Background: Rebound in psoriasis is, by definition, a rapid worsening of disease following the discontinuation of therapy for psoriasis; it occurs following the abrupt discontinuation of many therapies. To prevent...
7.
Leonardi C, Toth D, Cather J, Langley R, Werther W, Compton P, et al.
Dermatology
. 2006 Oct;
213(3):204-14.
PMID: 17033169
Background: Psoriasis is a chronic, incurable immune-mediated disease. Most therapies used for moderate to severe psoriasis are immunosuppressive. Agents that depress immune function, including traditional psoriasis therapies, have been associated...
8.
Langley R, Carey W, Rafal E, Tyring S, Caro I, Wang X, et al.
Clin Ther
. 2005 Nov;
27(9):1317-28.
PMID: 16291408
Background: Because many therapies for psoriasis disrupt the normal inflammatory cascade and could theoretically impair the body's ability to respond to external pathogens, a possible increase in the incidence of...
9.
Rieckmann P, OConnor P, Francis G, Wetherill G, Alteri E
Drug Saf
. 2004 Sep;
27(10):745-56.
PMID: 15350158
Introduction: Interferon-beta-1a (Rebif) is an established treatment for relapsing-remitting multiple sclerosis (MS) and haematological changes are commonly reported in clinical trials of this agent. The combined clinical trial and postmarketing...